Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced completion of enrollment in its Phase 1b clinical trial of PH-762, an siRNA compound ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE